Peijia Medical Co.

Peijia Medical Co.

Peijia Medical Co. was founded in 2012 and is headquartered in Suzhou, China. The company went public on the Hong Kong Stock Exchange in May 2020 (ticker 9996.HK). Its stated mission centers on providing safe, effective, and accessible medical solutions for patients suffering from cardiovascular and cerebrovascular diseases. Peijia operates across two primary therapeutic areas: structural heart disease and cerebrovascular interventions. Product lines include transcatheter aortic valve replacement (TAVR) systems, mitral and tricuspid valve repair devices, and a range of neurosurgical products for hemorrhagic and ischemic stroke, as well as access catheters. The firm develops and manufactures these devices internally, with a product portfolio that is among the more comprehensive in China (per company website). Geographically, Peijia is primarily focused on the Chinese market but maintains a global presence with offices in Europe, the Middle East, and the Americas. The company has not publicly disclosed total assets under management or deployment figures. Peijia's professional headcount is not known. Its principal investors include public market shareholders following the Hong Kong listing. The firm has not reported any significant M&A or fundraising events in the last 24 months. A distinguishing structural feature of Peijia is its position as a publicly listed medical device company, not a family office or investment vehicle. Unlike many entities covered by Altss, Peijia is an operating company with its own R&D, manufacturing, and commercial operations. Its capital allocation decisions, including R&D investment and potential acquisitions, are governed by its public company board and disclosed via stock exchange filings.